If your employer’s plan no longer covers a GLP-1 medication for weight loss starting January 1, 2027, you may be learning about the change during open enrollment, when you have limited time to compare options. For small-business owners, the same decision can mean balancing a valuable benefit against a renewal that is getting more expensive.

This is a real shift, but it does not mean every plan is dropping coverage. The practical step for both employers and employees is to check the actual 2027 plan documents and understand what alternatives, conditions, and costs apply.

What is changing for 2027?

A WTW health benefits survey, fielded in summer 2026, found that 53% of employers with more than 100 employees cover GLP-1 medications for weight loss, down from 57% in 2025. That is the first decline in three years. The survey also found that 16% of employers currently covering the medications are considering removing coverage, up from 9% a year earlier.

These figures describe surveyed employers, not every company or every health plan. Coverage may also be subject to conditions even when a medication appears on a plan’s drug list. Reporting by CNBC and USA Today points to more employers considering alternatives, including direct-to-consumer purchasing and weight-management programs.

The change comes as use has increased: Gallup reported that 11% of U.S. adults were taking GLP-1 medications for weight loss in 2026, compared with 3% in 2024; 15% said they had used one for weight loss at some point. A change to coverage can therefore affect employees who are actively taking a prescribed medication, not just people considering starting one.

Employee reviewing health benefits and discussing options with an advisor

Why employers are reconsidering coverage

In a survey of more than 1,800 U.S. employers, Marsh projected that health benefit costs per employee would rise an average of 8.2% in 2027, the largest increase since 2003. Marsh attributed a full percentage point of that overall cost growth to GLP-1 use. That projection already accounts for the cost-cutting steps employers say they plan to take, which is part of why coverage decisions are being revisited in this renewal cycle rather than a year from now.

For GLP-1 drugs used for weight loss, employers typically pay in the mid-$500s to mid-$600s per user per month through a traditional pharmacy benefit (the plan’s prescription coverage). That expense can add up quickly in a small group. For example, at an illustrative $600 per user each month, five users would cost $3,000 a month, or $36,000 over a year. This is simple arithmetic, not a prediction of any group’s claims or renewal, but it shows how a handful of claims can materially affect a small employer’s budget.

That pressure does not tell the whole story. Removing coverage can shift substantial expense to employees and disrupt treatment. For a business, the decision should account for plan terms, the group’s actual claims experience, available alternatives, and how the change will be communicated.

What small employers can do before renewal

Start with the written renewal and the plan’s drug list. Confirm whether weight-loss use of the medication remains covered for 2027 and ask what rules apply, including:

  • Diagnosis requirements: Does coverage require a diagnosed medical condition, and what documentation does the plan require?
  • Prior authorization: Must the prescribing clinician submit information and receive approval before the plan covers the medication?
  • Step therapy: Must an employee try another treatment first?
  • Quantity limits: Are there limits on the amount or duration covered?

Ask for the complete terms, not just a summary or a verbal answer, and get the renewal quote in writing early enough to review it before employees make enrollment decisions.

If costs are driving the discussion, compare more than a simple “cover it or drop it” choice. Ask what it would cost to keep the medication in the plan, and compare that with a carve-out or direct-to-employer reimbursement arrangement. In these models, an employer may remove the drug from the traditional pharmacy benefit but reimburse some of an employee’s out-of-pocket cost. The arrangement, eligibility, employee cost, and actual savings depend on its terms, so request a written comparison.

Another option is a weight-management program that offers coaching around nutrition and behavior change. Examples in recent reporting include CVS Weight Management, Noom, Omada Health, UnitedHealthcare’s Real Appeal, Vida, and Virta. Programs typically cost employers about $65 to $100 per employee per month; those that also provide prescriptions may cost $150 or more. Compare the services, participation requirements, pricing, and whether prescription support is included.

Most importantly, do not make a coverage cut without telling employees clearly and promptly. If someone discovers the change at the pharmacy counter in January, they may have little time to understand their options or discuss a treatment plan with their clinician.

Benefits documents and calculator on a desk during a plan comparison

What you can do if your coverage disappears

First, ask your employer or benefits administrator for the 2027 drug list, the plan’s coverage rules, and any exception or appeal process. If coverage requires prior authorization or other documentation, ask what information your clinician needs to provide. If the plan denies coverage, request the reason in writing and follow the plan’s stated review process.

You can also ask your clinician whether direct-to-consumer self-pay options are appropriate for you. As of November 2026, Novo Nordisk lists Wegovy starting at $149 a month for the pill and $199 a month for the shot; Eli Lilly lists Zepbound starting at $299 a month for a single-dose vial or multi-dose pen. These are starting prices, not a promise of the price for every dose or patient. Novo Nordisk says promotional pricing may be modified or canceled, so check current terms directly with NovoCare and LillyDirect.

Paying directly may not count toward your health plan deductible or out-of-pocket maximum. Confirm how the purchase would be treated under your plan before deciding what is affordable.

If a GLP-1 is prescribed to treat a diagnosed medical condition, such as obesity, it may be eligible for payment using FSA or HSA dollars. For 2027, the health FSA contribution limit is $3,500; HSA limits are $4,500 for individual coverage and $9,000 for family coverage, with a $1,000 catch-up contribution for people age 55 and older. Check your account administrator’s rules and keep documentation. An HSA can offer tax advantages, but using HSA funds now means those dollars are not left invested for future needs, including retirement. The IRS guide to medical expenses provides general information; it does not replace advice from your plan administrator or tax professional.

Do not stop or change a prescribed medication without talking with your doctor. Ask your clinician about the medical and financial options that may fit your circumstances.

Make the decision with facts, not assumptions

Dropping GLP-1 coverage does not make the underlying cost disappear; it changes who pays and how the medication is accessed. For a small group, the right path should be based on actual claims information and a clear comparison of plan terms, not a gut reaction to the renewal letter.

At Total Benefit Solutions Inc, we act as an independent advocate: we read the renewal, compare pharmacy terms across carriers, and push for answers when a covered drug is removed mid-year or a change is buried in an attachment. For small groups and sole proprietors, CIGNA PPO network self-funded options may also be worth comparing, subject to underwriting and availability; they are not a guaranteed fit for every group.

Visit www.totalbenefits.net or call 215-355-2121 to review your options and identify practical next steps.

We Work For Your Benefit.

#InsuranceAdvocacy #NeverAcceptNo #GLP1 #SmallBusinessBenefits #GroupHealthInsurance

Leave a Reply